Topics
March 2026 Supplement | Digital Supplement
Signaling for Sustained Change: Spotlight on the Potential of TKIs to Deliver Durable Control of Exudative Retinal Disease
November/December 2020 Supplement | Digital Supplement
The ACTS Program: Adding Testing to Your Defense Against COVID-19
Adopting a simple testing and safety platform for personal protective equipment and sterilization protocols adds a layer of protection for patients and office staff.
Joe Boyd
April 17, 2026
Phase 1 Data for Vamikibart Published in JAMA Ophthalmology
MeiraGTx Announces the Acquisition of XLRP Therapy From J&J
April 16, 2026
Experimental Light-Activated Therapy Shows Early Promise for Retinitis Pigmentosa
April 15, 2026
Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply for Ophthalmic Program
April 2026 Insert
Editorially independent supported by Abbvie and Regenxbio
April 2026 Supplement
Editorially independent content supported with advertising by EyePoint
Free Print Subscription
Email Newsletter
Conference Calendar
